Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How general practitioners assess risks in using new drugs.

P M Williamson

    The Journal of the Royal College of General Practitioners
    |May 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Rapid urinary tract infection diagnostics by surface-enhanced Raman spectroscopy (SERS): identification and antibiotic susceptibilities.

    Analytical and bioanalytical chemistry·2017
    Same author

    The role of sustained release isosorbide mononitrate on corticosteroid-induced hypertension in healthy human subjects.

    Journal of human hypertension·2015
    Same author

    Decreased threshold for the nitric oxide donor glyceryl trinitrate in cortisol-induced hypertension in humans.

    Clinical and experimental pharmacology & physiology·2007
    Same author

    The sydney multicentre study of Parkinson's disease: progression and mortality at 10 years.

    Journal of neurology, neurosurgery, and psychiatry·1999
    Same author

    Muscle sympathetic vasoconstrictor activity in hydrocortisone-induced hypertension in humans.

    Blood pressure·1998
    Same author

    Cortisol and hypertension.

    Clinical and experimental pharmacology & physiology. Supplement·1998

    Physicians assess situational risk, not just scientific drug risk, influencing pharmaceutical adoption. Past experiences with treatments, sponsors, and drug mechanisms shape perceived risks and validation needs.

    Area of Science:

    • Pharmaceutical adoption
    • Medical decision-making
    • Health innovation diffusion

    Background:

    • Physician adoption of new pharmaceuticals is influenced by perceived risks.
    • Situational risk, encompassing factors beyond scientific data, plays a crucial role.
    • Previous experiences with treatments, drug sponsors, and mechanisms of action inform risk perception.

    Purpose of the Study:

    • To explore the concept of 'situational risk' in pharmaceutical adoption.
    • To understand how physicians evaluate perceived risks beyond inherent drug safety.
    • To determine the factors influencing the need for additional validation before drug adoption.

    Main Methods:

    • Qualitative analysis of physician decision-making processes regarding new drug adoption.

    Related Experiment Videos

  • Examination of how past experiences and innovation characteristics shape risk assessment.
  • Exploration of the relationship between perceived risk and the need for further evidence.

    • Main Results:

    • Physicians' adoption decisions are significantly impacted by their perception of situational risk.
    • Factors such as sponsor reputation and mechanism of action critically influence perceived risk.
    • The extent of required validation is directly proportional to the physician's perceived situational risk.

    Conclusions:

    • Situational risk is a key driver in the adoption of new pharmaceuticals, independent of scientific risk.
    • Understanding physician perception of situational risk is vital for effective pharmaceutical innovation diffusion.
    • Tailoring validation strategies to address specific physician concerns can accelerate adoption.